Fudan University: clinical-trial pipeline
Fudan University is the sponsor of 1,307 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 565 are not yet finished and 39 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials565
Phase 2/3 and 3190
Countries1
New in 90 days39
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 537 |
| Not applicable | 476 |
| Phase 3 | 157 |
| Phase 4 | 36 |
| Phase 1/2 | 35 |
| Phase 2/3 | 33 |
| Phase 1 | 28 |
| Early phase 1 | 5 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 479 |
| Recruiting | 316 |
| Completed | 234 |
| Not yet recruiting | 198 |
| Active, not recruiting | 51 |
| Terminated | 16 |
| Withdrawn or not authorised | 11 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 1,115 |
| Gastroenterology and liver | 214 |
| Metabolic and endocrine (diabetes, obesity) | 51 |
| Nephrology and urology | 44 |
| Cardiovascular | 42 |
| Women's health and obstetrics | 41 |
| Infectious disease and vaccines | 31 |
| Neurology | 23 |
| Rare and genetic diseases | 19 |
| Respiratory | 19 |
| Haematology | 14 |
| Musculoskeletal | 13 |
Countries
| Country | Trials |
|---|---|
| China | 1,144 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-23 | New trial posted | First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresect… |
| 2026-10-20 | New trial posted | Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment |
| 2026-10-20 | New trial posted | Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer |
| 2026-10-16 | New trial posted | Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone… |
| 2026-10-16 | New trial posted | A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroes… |
| 2026-10-15 | New trial posted | MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer |
| 2026-10-14 | New trial posted | Artificial Intelligence-assisted Primary Care for Influenza Vaccination Among Chronic Pat… |
| 2026-10-14 | New trial posted | Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Tr… |
| 2026-10-08 | New trial posted | Family Physician Nudges for Influenza Vaccination Among Older Adults |
| 2026-10-06 | New trial posted | Hemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dyna… |
| 2026-10-02 | New trial posted | Vaccine Knowledge, Attitudes and Practices Among Men Who Have Sex With Men: a Global Cros… |
| 2026-10-02 | New trial posted | SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05668884 | GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | China |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | China |
| NCT07411443 | AI-Enhanced Imaging in Population Breast Cancer Screening | Not applicable | Recruiting | China |
| NCT04996732 | Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Regis… | Not applicable | Recruiting | China |
| NCT07798466 | Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery | Not applicable | Recruiting | China |
| NCT07117877 | Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Re… | Phase 2 | Not yet recruiting | China |
| NCT06786026 | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC | Phase 2 | Recruiting | China |
| NCT06652425 | Acute Effects of Cold Exposure on Cardiovascular System | Not applicable | Recruiting | China |
| NCT07312500 | Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer | Not applicable | Active, not recruiting | China |
| NCT05098847 | Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis fro… | Phase 2 | Recruiting | China |
| NCT07752719 | APEX-STROKE CALM-ICH Domain | Phase 3 | Not yet recruiting | |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as Firs… | Phase 2 | Not yet recruiting | China |
| NCT07514793 | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced… | Phase 2 | Not yet recruiting | China |
| NCT07605663 | an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer | Not applicable | Active, not recruiting | China |
| NCT07574749 | Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Effic… | Not applicable | Recruiting | China |
| NCT06547736 | Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer | Phase 2 | Recruiting | China |
| NCT06943781 | Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detec… | Not applicable | Recruiting | China |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | Phase 2 | Not yet recruiting | |
| NCT05881746 | Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-… | Not applicable | Not yet recruiting | China |
| NCT07705438 | Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | Not applicable | Recruiting | China |
| NCT06652932 | Acute Effects of Low Temperature Exposure on Respiratory System | Not applicable | Active, not recruiting | China |
| NCT06404736 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer | Phase 2 | Not yet recruiting | China |
| NCT05727085 | Cohort of Twin Pregnancy and the Offspring | Not applicable | Recruiting | China |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | Phase 2 | Recruiting | China |
| NCT05969899 | Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer | Phase 2 | Active, not recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Fudan University clinical trials: 565 open, 190 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/fudan-university/, data as of 2026-10-25.